Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

ABSTRACT:

Purpose

Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently showed improved progression-free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. This study examined potential genetic markers associated with response and PFS in the phase I study of dabrafenib.

Experimental design

Baseline (pretreatment or archival) melanoma samples were evaluated in 41 patients using a custom genotyping melanoma-specific assay, sequencing of PTEN, and copy number analysis using multiplex ligation amplification and array-based comparative genomic hybridization. Nine patients had on-treatment and/or progression samples available.

Results

All baseline patient samples had BRAF(V600E/K) confirmed. Baseline PTEN loss/mutation was not assoc

SUBMITTER: Nathanson KL 

PROVIDER: S-EPMC3924894 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature